Belluscura PLC Belluscura Expands its Patent Portfolio

TIDMBELL

Belluscura PLC

19 May 2022

Belluscura PLC

("Belluscura" or the "Company")

Belluscura Expands its Oxygen Enrichment Patent Portfolio

Three New Patents Issue related to Extracorporeal membrane oxygenation (ECMO), Continuous Positive Airway Pressure (CPAP) and Replaceable Molecular Sieve Technology

LONDON, U.K. AND PLANO, TX, U.S. (19 May 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that three additional US patents have recently issued, increasing the number of issued and pending patent applications the Company owns or exclusively licenses to thirty.

The technology covered by the patents, includes:

-- Extracorporeal membrane oxygenation (ECMO) innovations for when people who are very ill with conditions of the heart and lungs, or who are waiting for or recovering from a heart transplant, require a portable artificial lung;

-- Continuous Positive Airway Pressure (CPAP) innovations, a type of non-invasive ventilation (NIV) or breathing support, and;

-- Consumer replaceable molecular sieve technology, used to remove Nitrogen from ordinary air to produce medical grade supplemental oxygen.

Robert Rauker, CEO of Belluscura plc, said: "Our pioneering engineering team continues to develop next generation oxygen enrichment technology along with our research partner, Separation Design Group. We see significant expanding future opportunities in the supplemental oxygen field."

For further information please contact:

 
 Belluscura plc                                                          www.belluscura.com 
 Robert Rauker, Chief Executive                                             via Walbrook PR 
  Officer 
 Anthony Dyer, Chief Financial 
  Officer 
 
 SPARK Advisory Partners Limited                                   Tel: [phone] 
  (NOMAD) 
 Neil Baldwin 
 
 Dowgate Capital Limited (Broker)                                  Tel: [phone] 
 James Serjeant / Nicholas Chambers 
 
 Walbrook PR Ltd (Media & Investor    Tel: [phone] or [e-mail] 
  Relations) 
 Paul McManus / Sam Allen                            Mob: [phone] 
                                                                                    558 258 
 

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASFMESAEESEDI

(END) Dow Jones Newswires

May 19, 2022 02:02 ET (06:02 GMT)